Physician profile
Jayne Murphy-Bryner
NPI 1851792196
$1,986.30
in general payments reported to CMS, 2019-2025
23 companies · $810 in 2025
The $810 reported for 2025 was more than what 83% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.36 · 2022: $314 · 2023: $174 · 2024: $606 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,590.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,590.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $317.98 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $266.43 | 2021-2025 | Farxiga, Airsupra |
| Novo Nordisk INC | $251.65 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $143.72 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $134.17 | 2024-2025 | Mounjaro, Zepbound |
| Lundbeck LLC | $132.04 | 2024-2025 | Rexulti |
| Pfizer INC. | $128.28 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $116.93 | 2024-2025 | Spravato |
| Glaxosmithkline, LLC. | $64.21 | 2024-2025 | Trelegy Ellipta, Arexvy, Bexsero |
| Phathom Pharmaceuticals, INC. | $61.51 | 2024-2025 | Voquezna |
| Astellas Pharma US INC | $49.84 | 2024-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company LTD. | $45.00 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.37 | 2023-2024 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $43.95 | 2024 | Rexulti |
| Sage Therapeutics, LLC | $37.13 | 2024-2025 | Zurzuvae |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $29.42 | 2022 | |
| Mayne Pharma Commercial LLC | $27.50 | 2023 | |
| Noven Therapeutics, LLC | $18.86 | 2025 | Xelstrym |
| Xeris Pharmaceuticals, INC. | $18.30 | 2025 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $17.44 | 2023 | Krystexxa |
| Ucb, INC. | $13.52 | 2023 | Briviact |
| Takeda Pharmaceuticals U.S.A., INC. | $12.13 | 2022 | |
| Eisai INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayne Murphy-Bryner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.